Our website uses necessary cookies to enable basic functions and optional cookies to help us to enhance your user experience. Learn more about our cookie policy by clicking "Learn More".
Accept All Only Necessary Cookies
Tivatrainer icon

0.0.47 by gutta


May 26, 2024

About Tivatrainer

English

Simulation app to teach pharmacokinetic of Intravenous Anaesthetics.

A simulation program to explain and teach pharmacokinetic behaviour of Intravenous Anaesthetics and other drugs. Its purpose is education at the point of care. Where applicable the effect on the BIS is displayed. Copy paste between simulations now available. There are a number of intravenous drugs that come with the application but you can also access a central database and download other drug records for off-line use. Interaction between Propofol and opioids is implemented. An exceptional feature is the IVassist mode that will calculate a manual dosing scheme to obtain and change a target blood or effect site concentration with adjustable precision. This will allow to show an example of a TCI like administration of drugs and Pk models that are not yet available in TCI systems and evaluate that model. Simulation data can be exported to your favourite spreadsheet for later analysis.

What's New in the Latest Version 0.0.47

Last updated on May 26, 2024

Please visit https://www.tivatrainer.com/changes/ for the list of changes in this update!

Translation Loading...

Additional APP Information

Latest Version

Request Tivatrainer Update 0.0.47

Uploaded by

Adi Masky

Requires Android

Android 4.4+

Available on

Get Tivatrainer on Google Play

Show More

Tivatrainer Screenshots

Comment Loading...
Languages
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.